Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.
OBJECTIVE
To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.


METHODS
Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m(2) iv on day 1, heptaplatin 400 mg/m(2) iv on day 2 and 5-fluorouracil 800 mg/m(2) on day 2 approximately 4 were administered and the regimen was repeated every 3 weeks.


RESULTS
The median age of the patients was 60 years (range: 32 approximately 74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26 approximately 8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48 approximately 6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26 approximately 17.44). A median of 3 cycles (range: 1 approximately 7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life-threatening complication of pneumonia.


CONCLUSIONS
The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed.
Ahn
Myung-Ju
MJ
Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea. ahnmj@hanyang.ac.kr
Oh
Ho-Suck
HS
Choi
Jung-Hye
JH
Lee
Young-Yeul
YY
Kim
In-Soon
IS
Choi
Il-Young
IY
Lee
Oh Young
OY
Choi
Ho-Soon
HS
Kwon
Sung-Joon
SJ
Am J Clin Oncol. 1999 Dec;22(6):580-6
10597742
J Clin Oncol. 1992 Apr;10(4):541-8
1548519
J Clin Oncol. 2004 Jan 1;22(1):23-30
14665611
Cancer Chemother Pharmacol. 1998;41(2):109-16
9443623
J Clin Oncol. 2000 Jul;18(14):2648-57
10894863
Cancer. 1999 Oct 1;86(7):1109-15
10506693
Br J Cancer. 2000 Aug;83(4):458-62
10945491
Cancer. 1993 Jun 15;71(12):3813-8
8508349
Ann Oncol. 1994 Feb;5(2):189-90
8186165
Cancer. 1999 Jan 15;85(2):295-301
10023695
J Clin Oncol. 1997 Jan;15(1):261-7
8996151
Cancer Res Treat. 2003 Apr;35(2):117-22
26680924
Cancer. 1993 Jul 1;72(1):37-41
8508427
Cancer Res Treat. 2002 Apr;34(2):77-83
26680846
Br J Cancer. 1995 Mar;71(3):587-91
7533517
Cancer Chemother Pharmacol. 1995;37(1-2):1-6
7497577
Oncology. 2000 Apr;58(3):191-7
10765119